Table 1 Clinical characteristics of Finnish prostate cancer patients.
From: Novel prostate cancer susceptibility gene SP6 predisposes patients to aggressive disease
Total PrCa sample size | n = 2738 (%) |
|---|---|
Age at diagnosis (years) | |
≤55, young onset | 106 (3.90) |
>55 | 2632 (96.1) |
Diagnostic PSA level, ng/mL | |
Low, ≤20 | 2099 (76.7) |
High, >20 | 484 (17.3) |
Missing data | 155 (5.66) |
Gleason score | |
Low, ≤6 | 1320 (48.2) |
High, ≥8 | 368 (13.4) |
Gleason 7 | 685 (25.0) |
Missing data | 365 (13.3) |
T stage | |
T0/Tx | 13 (0.48) |
T1 | 1105 (40.4) |
T2 | 972 (35.5) |
T3 | 443 (16.2) |
T4 | 97 (3.54) |
Missing data | 108 (3.95) |
N stage | |
N0/Nx | 2616 (95.5) |
N1 | 14 (0.51) |
Missing data | 108 (3.95) |
M stage | |
M0/Mx | 2439 (89.1) |
M1 | 191 (6.98) |
Missing data | 108 (3.95) |
PSA progression | |
Progressed | 960 (35.1) |
Missing data | 1778 (65.0) |
Vital status | |
Deceased of PrCa | 298 (10.9) |
Deceased of else | 928 (33.9) |
Alive | 1512 (55.2) |
Aggressive PC | |
Yesa | 1019 (55.9) |
Nob | 804 (44.1) |
